Dianthus Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Welcome to the Dianthus Therapeutics company presentation. My name is Ethan Taylor. I'm an associate in JPMorgan's Healthcare Investment Banking Group. It is my pleasure to introduce Marino Garcia, President and CEO of Dianthus. A quick note, there'll be a few minutes towards the end of the presentation for some audience Q&A, so please have some questions ready. And with that, Marino, please take away.
Thank you, Ethan, and thank you to the JPMorgan team for this opportunity to tell you a little bit about Dianthus, and the great work our team is doing, and the exciting times ahead. Before I jump in, just a caution, I'll be making some forward-looking statements. I urge everyone to go to our website and get more details there, where you can also access all our SEC filings.
So Dianthus was founded in 2019 to develop what we're calling next-generation complement therapies to treat severe autoimmune
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |